BridgeBio to stop development of therapy for genetic disorder, ET HealthWorld

London: BridgeBio Pharma said on Tuesday it will stop development of its experimental therapy for a genetic disease that affects the adrenaline-producing gland.

The drugmaker said the results of its early-to-mid stage study testing the therapy did not meet the threshold to warrant additional capital investment.

It will reduce its gene therapy development budget by more than $50 million, and seek partnership opportunities to support future development of the therapy, BBP-631, or newer treatments for congenital adrenal hyperplasia (CAH).

CAH is a group of genetic disorders caused by a mutation in an enzyme needed to produce cortisol, which is secreted by the adrenal gland.

The study showed that higher doses of BBP-631 increased production of cortisol in all patients.

Cortisol helps the body to respond to injury, stress or illness.

(Reporting by Puyaan Singh in Bengaluru; Editing by Shinjini Ganguli)